Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
LAUSANNE, Switzerland--(Business Wire/Korea Newswire)--Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of ...
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


